Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.35), $0.17 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $4.48 million.

“The third quarter results showed the tremendous response from the diabetes community to the highly anticipated launch of our Gvoke HypoPen. Across the country, prescriptions have grown steadily even in the midst of the ongoing pandemic as families have sought to have the rapid and reliable profile of the Gvoke HypoPen readily available in the event of a hypoglycemic episode,” said Paul R. Edick, Xeris’ Chairman and Chief Executive Officer. “As we look ahead to early next year, we anticipate a European regulatory decision on our ready-to-use glucagon for severe hypoglycemia and three FDA meetings for post-bariatric hypoglycemia, exercise-induced hypoglycemia, and pramlintide-insulin for diabetes blood sugar control.”

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.